Table III.

Comparison of HLA-DR specificities and alleles according to disease course in past and current patients with Lyme arthritisa

HLA-DR
 specificityPast patients with
 Lyme arthritisOR (95% CI)HLA-DRB1 allelesCurrent patients with
 Lyme arthritisOR (95% CI)
Moderate or
 prolongedbBriefcAntibiotic
 refractorydAntibiotic
 responsivee
%%%%
DR121181.17 (0.35, 3.89)0101, 0102, 010328181.79 (0.75, 4.27)
DR241183.18 (0.99, 10.04)1501, 1502, 160132201.92 (0.83, 4.43)
DR321230.89 (0.28, 2.77)030120320.51 (0.23, 1.19)
DR44096.75 (1.54, ND)f401/02/03/04/05/06/07/08/
     09/1646262.47 (1.13, 5.37)
DR517320.45 (0.15, 1.34)1101/02/03/04, 120117360.36 (0.16, 0.84)
DR714180.72 (0.20, 2.52)070123181.33 (0.54, 3.24)
  • a The results in past patients were published previously (7). The 80 patients were stratified according to the longest single attack of arthritis. Analogous to the current definition of antibiotic-responsive arthritis, arthritis of ≤3-mo duration in past patients was defined as arthritis of brief duration, and analogous to the current definition of antibiotic-refractory arthritis, arthritis lasting 4 mo to 4 yr in past patients was defined as arthritis of moderate or prolonged duration.

  • b n = 58.

  • c n = 22.

  • d n = 71.

  • e n = 50.

  • f The number of patients with the DR4 specificity in the brief group was too small to calculate a reliable upper CI.